A placebo-controlled trial has shown that the oral AKT inhibitor engasertib could reduce the frequency and duration of ...
A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for ...
Hereditary hemorrhagic telangiectasia (HHT) can cause recurrent, severe epistaxis, as well as anemia and reduced quality of ...
Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...
Vaderis Therapeutics today announced that data from its randomized, double-blind, placebo-controlled, multi-center ...
Data demonstrate that ATV-1601, a selective allosteric inhibitor of AKT1 E17K, provides enhanced target inhibition, superior efficacy and improved tolerability compared to pan-AKT inhibitors in ...
SAN ANTONIO -- Addition of an investigational AKT inhibitor to standard fulvestrant (Faslodex) doubled median progression-free survival (PFS) in the second-line setting for patients with hormone ...
Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical insights and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719. This is an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback